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with or without asthma.  Results: The proportion of subjects 
experiencing adverse events (AEs) was greater in the active 
treatment group (12 SQ-HDM; 73% of subjects) compared to 
placebo (53%). The most common treatment-related AEs 
were local allergic reactions. No AEs were reported as sys-
temic allergic reactions. Regardless of asthma status, most 
AEs were mild or moderate (>97% of AEs) and the frequency 
of serious AEs was low. Subgroup analysis revealed no statis-
tically significant difference in the risk of experiencing mod-
erate or severe treatment-related AEs for subjects with asth-
ma compared to subjects without asthma ( p = 0.88). In addi-
tion, subjects with partly controlled or uncontrolled asthma 
were no more likely to experience moderate or severe treat-
ment-related AEs than subjects with controlled asthma ( p = 
0.42).  Conclusion: The SQ HDM SLIT-tablet is well tolerated, 
and the safety profile was comparable for subjects with HDM 
respiratory allergic disease irrespective of asthma status.
 © 2017 The Author(s)
Published by S. Karger AG, Basel 
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 Abstract 
 Background: The SQ house dust mite (HDM) SLIT-tablet 
(ALK, Denmark) addresses the underlying cause of HDM re-
spiratory allergic disease, and a clinical effect has been dem-
onstrated for both HDM allergic rhinitis and allergic asthma. 
Here, we present pooled safety data from an adult popula-
tion with HDM respiratory allergy, with particular focus on 
the impact of asthma on the SQ HDM SLIT-tablet tolerability 
profile.  Methods: Safety data from 2 randomised double-
blind, placebo-controlled clinical trials were included: MT-
04: 834 adults with HDM allergic asthma not well controlled 
by inhaled corticosteroids and with HDM allergic rhinitis, 
and MT-06: 992 adults with moderate-to-severe HDM aller-
gic rhinitis despite the use of allergy pharmacotherapy and 
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 Introduction 
 House dust mite (HDM) respiratory allergic disease 
has 2 main clinical manifestations: allergic rhinitis and 
allergic asthma  [1] . The vast majority of patients with 
HDM respiratory allergy suffer from allergic rhinitis and 
almost half have concomitant allergic asthma  [2] . Many 
patients have persistent symptoms all year  [3, 4] .
 In addition to allergy immunotherapy (AIT), current 
treatment options for HDM respiratory allergic disease 
include allergen avoidance and allergy pharmacotherapy. 
However, allergen avoidance is often not sufficient, and 
studies suggest that a substantial proportion of patients 
experience inadequate symptomatic control by allergy 
pharmacotherapy  [5–7] . The AIT treatment effect is gen-
erally well established for allergic rhinitis  [8] , but the use 
of AIT in allergic asthma is not adequately documented 
due to a lack of well-designed clinical trials  [9, 10] .
 Consequently, international asthma treatment guide-
lines have been reluctant to accept AIT as a treatment op-
tion for allergic asthma  [11] . This reluctance is based on 
a notion that the available AIT efficacy evidence in aller-
gic asthma is not sufficient for outweighing the risks of 
AIT, which have been considered to constitute a particu-
lar problem in patients with asthma  [11] . Deaths have oc-
curred with subcutaneously administered AIT (SCIT) 
and studies have reported an estimated incidence of fatal 
reactions in 1 of 2.5 million injections  [12, 13] . Most fatal 
reactions (88%) involved asthmatic patients, and patients 
with not well-controlled asthma appeared to be at highest 
risk  [13] . Thus, some national treatment guidelines con-
sider uncontrolled and severe asthma to be contraindica-
tions for AIT  [14, 15] .
 In the past decade, a number of well-powered clinical 
trials with sublingual immunotherapy (SLIT) have been 
published, in particular with SLIT-tablets  [16–25] , and 5 
SLIT-tablet products (2 grass SLIT-tablets, 2 HDM SLIT-
tablets, 1 ragweed SLIT-tablet) are now authorised for at-
home treatment of allergic rhinitis in different regions of 
the world. As the only one, the SQ HDM SLIT-tablet is 
authorised for treatment of both HDM allergic rhinitis 
and allergic asthma in a number of countries in Europe 
and in Australia. While treatment initiation is contrain-
dicated in patients with impaired lung function (FEV 1 
<70% of predicted value) and in patients who have expe-
rienced a severe asthma exacerbation within the last 3 
months, the overall picture indicates a safety and tolera-
bility profile of SLIT-tablets which is more benign than 
that of SCIT  [26] , on which the concerns regarding asth-
ma were originally based. This is particularly relevant for 
HDM respiratory allergy patients, about half of whom 
have allergic asthma  [2] .
 The safety and tolerability of the SQ HDM SLIT-tablet 
were tested in 2 phase I trials  [27] , and subsequently clin-
ical efficacy in both HDM allergic asthma and HDM al-
lergic rhinitis has been demonstrated in 6 published ran-
domised, double-blind, placebo-controlled efficacy trials 
 [22, 24, 25, 28–32] . The present study reports pooled safe-
ty and tolerability data from the 2 phase III trials that 
formed part of the basis for regulatory approval in several 
European countries and in Australia; the 2 trials covered 
a broad European population of adult patients with HDM 
respiratory allergy. Particular focus is on the impact of al-
lergic asthma on the safety and tolerability profile of the 
SQ HDM SLIT-tablet. Data for the dose approved in Eu-
rope and Australia (12 SQ-HDM) are presented.
 Materials and Methods 
 MT-04 and MT-06 were both randomised, double-blind, pla-
cebo-controlled phase III clinical trials (EudraCT No. 2010-
018621-19 and 2011-002277-38, respectively) ( Table 1 ) designed 
and conducted in accordance with the principles of the Declara-
tion of Helsinki (1964, and its amendments and subsequent clari-
fications)  [33] and Good Clinical Practice  [34] . The primary objec-
tive of MT-04 was to demonstrate effective and tolerable treatment 
of HDM allergic asthma  [24] , while the primary objective of MT-
06 was to demonstrate effective and tolerable treatment of HDM 
allergic rhinitis in adults with HDM respiratory allergic disease 
 [25] . FEV 1 <70% of predicted value after adequate pharmacologi-
cal treatment at randomisation and a severe asthma exacerbation 
within the last 3 months prior to randomisation were exclusion 
criteria in both trials.
 The SQ HDM SLIT-tablet (ALK, Denmark) is a rapidly dissolv-
ing freeze-dried tablet containing a 1: 1 mixture of allergen extracts 
from the HDM species  Dermatophagoides  pteronyssinus and  D. 
farinae . Source material of bodies and faeces makes certain the 
tablet contains the broadest possible spectrum of major and minor 
allergens from these HDM species. A highly standardised produc-
tion process ensures a 1: 1:1: 1 ratio of the Der p 1, Der f 1, Der p 2, 
and Der f 2 major allergens  [35] .
 Initial administration of the SQ HDM SLIT-tablet was per-
formed under physician supervision followed by monitoring for at 
least 30 min. Pooled data from the 2 trials were used to describe 
the overall safety profile, most common treatment-related AEs 
(AEs assessed by the investigator as being related to the treatment), 
and severe treatment-related AEs. Pooled data were also used to 
describe the onset and duration of the most common treatment-
related AEs. In addition, treatment-related serious adverse events 
(SAEs, i.e., life-threatening AEs or AEs that resulted in death, hos-
pitalisation, congenital anomaly, disability, or permanent damage, 
or that required intervention to prevent permanent damage) were 
described. Further, the safety results were analysed to reveal differ-
ences in safety and tolerability that might arise from differences in 
severity of HDM allergic asthma.
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 All AEs observed by the investigators or reported by the sub-
jects were recorded. Included in this pooled analysis are all AEs 
occurring after the first administration of treatment. Investigators 
assessed the seriousness, severity, and possible relationship to 
treatment (causality) for all AEs. AEs, including SAEs, were de-
fined according to the ICH Harmonised Tripartite Guideline E2A 
 [36] and coded using the Medical Dictionary for Regulatory Ac-
tivities (MedDRA). For further details on the recording and clas-
sification of AEs, please see the online supplementary material 
(www.karger.com/doi/10.1159/000478699).
 In the MT-04 trial, subjects’ baseline asthma control was as-
sessed by their Asthma Control Questionnaire (ACQ) score and 
subsequently, a pre-specified translation to Global Initiative for 
Asthma (GINA) control criteria was performed  [29, 31] .
 Results 
 Trial Population 
 A table of subject disposition pooled from the 2 trials 
is found in this article’s online supplementary material 
(online suppl. Table S1). A total of 1,215 adult subjects 
were included in the analysis: 600 randomised to the SQ 
HDM SLIT-tablet (dose 12 SQ-HDM) and 615 to place-
bo. The overall proportion of subjects who discontinued 
the trials was similar in both treatment groups (19% of 
subjects on active treatment and 18% on placebo). When 
looking specifically at trial discontinuations due to AEs, 
the proportion was greater among subjects on active 
treatment (6% of subjects) compared to placebo (2%).
 Both trials were conducted in Europe; 52% of the trial 
population was male, and more than 99% of subjects were 
Caucasian. The mean age was 33 years (range 17–83 
years). Approximately two-thirds of the subjects were 
sensitised to other airborne allergens in addition to HDM 
(e.g., pollen, mould, and dander). All 1,215 subjects had 
a clinical history of HDM allergic rhinitis, and 863 (71%) 
also had HDM allergic asthma. The average history of 
HDM allergic rhinitis was 12 years (median 9 years) and 
the average history of HDM allergic asthma was 12 years 
(median 8 years). In the MT-04 trial, in which all subjects 
were required to have HDM allergic asthma per trial in-
clusion criteria, the mean FEV 1 at randomisation was 
93% of the predicted value. In addition, the MT-04 trial 
population was required to have HDM allergic asthma 
which was not well-controlled by inhaled corticosteroids 
(ICS; mean daily ICS dose at randomisation was 588 μg 
budesonide), as defined by an ACQ score of 1–1.5 (mean 
ACQ score at randomisation was 1.23)  [24] . In the MT-06 
trial, in which subjects were only required to have HDM 
 Table 1.  Overview of included trials with the SQ HDM SLIT-tablet
Trial Treatment Population Rhinitis Asthma
MT-04 (phase III)
EudraCT: 2010-
018621-19 [24]
6 or 12 SQ-HDM or
placebo, 13 – 19 months
of treatment
834 adults HDM allergic rhinitis, no 
requirements for severity or 
medication use
HDM allergic asthma not well 
controlled by ICS corresponding 
to the doses used at GINA 
medication steps 2 – 4
MT-06 (phase III)
EudraCT: 2011-
002277-38 [25]
6 or 12 SQ-HDM or
placebo, 1 year of
treatment
992 adults Moderate-to-severe HDM allergic 
rhinitis with a high level of 
symptoms and impaired quality of 
life despite frequent medication use
Mild asthma controlled by ICS 
(GINA medication steps 1 – 2) 
allowed but not required
HDM, house dust mite; ICS, inhaled corticosteroids; GINA, Global Initiative for Asthma.
 Table 2.  Overall AE summary for adult subjects in the 2 trials
12 SQ-HDM
(N = 600)
  Placebo
(N = 615)
n %n e %e  n %n e %e
All AEs 435 73 1,511 100 328 53 835 100
Causality
Possibly 297 50 808 53 98 16 165 20
Unlikely 305 51 703 47 295 48 670 80
Severity
Mild 365 61 1,055 70 256 42 550 66
Moderate 203 34 423 28 148 24 258 31
Severe 27 5 33 2 24 4 27 3
Seriousness
Serious 7 1 10 1 19 3 20 2
Not serious 434 72 1,501 99  324 53 815 98
 AE, adverse event; n, number of subjects with event; %n, per-
centage of subjects with event; e, number of events; %e, percentage 
of events.
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allergic rhinitis, 46% of subjects had mild HDM allergic 
asthma. Across both trials, mean FEV 1 at randomisation 
was 98% of the predicted value.
 Overall, in the pooled population, 559 subjects (46%; 
from the MT-04 trial) were classified as having uncon-
trolled or partially controlled asthma (according to GINA 
control criteria), as characterised by higher mean daily 
ICS use, higher daytime asthma symptom score, lower 
FEV 1 , more nocturnal awakenings, and higher short-act-
ing β-agonist intake at randomisation. This subgroup 
with uncontrolled/partially controlled HDM allergic 
asthma was investigated specifically with regard to the 
safety profile.
 Overall Safety Profile 
 Table 2 provides a summary of AEs reported in the 2 
trials. The proportion of subjects experiencing AEs was 
greater in the active treatment group compared to pla-
cebo (73 vs. 53% of subjects, respectively). For AEs as-
sessed as possibly related to treatment, this difference was 
even more pronounced, with 50% of subjects on active 
treatment reporting treatment-related AEs compared to 
16% of subjects on placebo. A slightly larger proportion 
of subjects experienced AEs leading to trial discontinua-
tion in the active treatment group (6%) compared to pla-
cebo (2%). Numbers were similar in both treatment 
groups with regard to the severity of AEs (distribution of 
mild, moderate, and severe AEs) and the frequency of 
SAEs ( Table 2 ).
 Safety Profile in Subjects Based on Asthma Status 
 When comparing the overall safety data for subjects 
with and without asthma, a number of minor differences 
were observed, as specified in the following. Among sub-
jects on active treatment, a greater proportion of subjects 
with asthma (75%) reported AEs compared to subjects 
without asthma (66%). However, fewer subjects with 
asthma (48%) reported treatment-related AEs compared 
to subjects without asthma (53%). Regardless of asthma 
status, the vast majority of reported AEs were mild or 
moderate (>97% of AEs in both subgroups) and the fre-
quency of SAEs was low (3% of subjects with asthma ex-
perienced SAEs compared to 1% of subjects without asth-
ma).
 Specific subgroup analyses were conducted to reveal 
potential differences in the safety profile of the SQ HDM 
SLIT-tablet based on subjects’ asthma status.  Figure 1 
presents a forest plot of the differences between treatment 
Subgroup Risk difference with 95% CI Estimate and 95% CI  n/N (%) Inter-
action
p value
Plc-Act lower
limit
upper 
limit
place bo 12 SQ-HDM
Asthma status 0.883
Asthma –0.07 –0.11 –0.04 19/429 (4) 51/434 (12)
No asthma –0.07 –0.13 –0.02 7/186 (4) 18/166 (11)
GINA steps 0.267
1 – 2 –0.09 –0.14 –0.04 8/237 (3) 26/215 (12)
3 – 4 –0.06 –0.11 –0.00 11/190 (6) 25/217 (12)
Asthma control 0.415
Controlled –0.10 –0.16 –0.04 6/152 (4) 21/152 (14)
Partially/uncontrolled –0.06 –0.10 –0.02 13/277 (5) 30/282 (11)
Mono- vs. poly-sensitised 0.096
Mono-sensitised –0.08 –0.12 –0.04 3/208 (1) 19/200 (10)
Poly-sensitised –0.07 –0.11 –0.03 23/407 (6) 50/400 (13)
IgE level 0.052
≤17.5 kU/L –0.01 –0.07 0.04 10/159 (6) 12/160 (8)
>17.5 kU/L –0.09 –0.14 –0.04 7/212 (3) 27/226 (12)
The p value is from the test statistic for testing the interaction between the treatment and any subgroup variable.
–1.0 –0.5 0 0.5 1.0
 Fig. 1. Forest plot of differences in proportions of subjects with moderate or severe treatment-related adverse 
events in various subgroups (MT-04 + MT-06 full analysis set). GINA step subgroups include subjects based on 
level of asthma medication at screening. Mono-sensitised includes subjects sensitised to house dust mite (HDM) 
only; poly-sensitised includes subjects sensitised to allergens beyond HDM. Plc-Act, placebo-active.
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groups in the proportion of subjects experiencing moder-
ate or severe treatment-related AEs in specific subgroups. 
As expected, based on the overall safety profile, more sub-
jects on active treatment experienced treatment-related 
AEs compared to the placebo group. As presented in  Fig-
ure 1 , this was the case irrespective of asthma status. Sub-
group analysis by asthma status revealed no statistically 
significant difference in the risk of experiencing moder-
ate or severe treatment-related AEs for subjects with asth-
ma compared to subjects without asthma ( N asthma = 863, 
 N no asthma = 352;  p = 0.88). Among subjects on active treat-
ment, 12% with asthma and 11% without asthma report-
ed events. Likewise, the proportion was 12% regardless of 
subjects’ level of asthma medication (GINA step) at 
screening, and subgroup analysis based on GINA medi-
cation step at screening did not show any statistically sig-
nificant impact ( p = 0.27).
 When comparing subjects with uncontrolled or par-
tially controlled asthma at treatment initiation ( n = 559) 
to subjects with controlled asthma ( n = 304), overall safe-
ty data revealed a greater proportion of subjects reporting 
AEs among subjects with partly or uncontrolled asthma 
(70% of subjects) compared to subjects with controlled 
asthma (57%). Similarly, more subjects with partly or un-
controlled asthma experienced severe AEs (6%) com-
pared to subjects with controlled asthma (2%). In con-
trast, when looking specifically at AEs related to treat-
ment, the proportion of subjects reporting events was 
similar for subjects with controlled asthma (52% on 12 
SQ-HDM; 11% on placebo) compared to subjects with 
partly controlled or uncontrolled asthma (46% on 12 SQ-
HDM; 17% on placebo). This was supported by specific 
subgroup analysis of the proportion of subjects experi-
encing moderate or severe treatment-related AEs ( Fig. 1 ), 
which showed that subjects with uncontrolled or partial-
ly controlled asthma were no more likely to experience 
moderate or severe treatment-related AEs than subjects 
with controlled asthma (11 and 14% of subjects on active 
treatment, respectively). Thus, the risk of experiencing 
treatment-related AEs was not influenced by asthma con-
trol (controlled vs. uncontrolled/partially controlled 
asthma,  p = 0.42) ( Fig. 1 ).
 Figure 2 shows the risk of experiencing moderate or 
severe treatment-related AEs over time, depicted as haz-
ard ratios for the various subgroups. Across all subgroups, 
hazard ratios were less than 1, indicating an increased risk 
of treatment-related AEs in the active treatment group 
compared to placebo. No statistically significant differ-
Subgroup Hazard ratio with 95% CI  Estimate and 95% CI N (%) Inter-
action
p value
Plc-A ct lower 
limit
upper 
limit
placebo 12 SQ-HDM
Asthma status 0.889
Asthma 0.36 0.21 0.61 429 (70) 434 (72)
No asthma 0.33 0.14 0.80 186 (30) 166 (28)
GINA steps 0.265
1 – 2 0.26 0.12 0.58 237 (56) 215 (50)
3 – 4 0.48 0.23 0.97 190 (44) 217 (50)
Asthma control 0.410
Controlled 0.27 0.11 0.67 152 (35) 152 (35)
Partially/uncontrolled 0.42 0.22 0.81 277 (65) 282 (65)
Mono- vs. poly-sensitised 0.108
Mono-sensitised 0.15 0.04 0.50 208 (34) 200 (33)
Poly-sensitised 0.43 0.26 0.70 407 (66) 400 (67)
IgE level 0.054
≤17.5 kU/L 0.83 0.36 1.92 159 (43) 160 (41)
>17.5 kU/L 0.26 0.11 0.60 212 (57) 226 (59)
The p value is from the test statistic for testing the interaction between the treatment and any subgroup variable.
0 0.5 1.0 1.5 2.0
 Fig. 2. Forest plot of hazard ratio for subjects with moderate or severe treatment-related adverse events in various 
subgroups (MT-04 + MT-06 full analysis set). GINA step subgroups include subjects based on level of asthma 
medication at screening. Mono-sensitised includes subjects sensitised to house dust mite (HDM) only; poly-
sensitised includes subjects sensitised to other allergens in addition to HDM. Plc-Act, placebo-active. 
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ences were observed between subgroups (asthma vs. no 
asthma,  p = 0.89; GINA step 1–2 vs. step 3–4,  p = 0.27; 
controlled vs. uncontrolled/partially controlled asthma, 
 p = 0.41).
 Safety Profile in Subjects Based on Sensitisation Status 
and Specific IgE Level 
 As presented in  Figures 1 and  2 , subgroup analyses 
based on subjects’ sensitisation status revealed no signifi-
cant differences in the risk of experiencing moderate or 
severe treatment-related AEs between subjects only sen-
sitised to HDM and subjects sensitised to additional al-
lergens ( p  ≥ 0.1).
 When comparing subjects based on serum levels of 
HDM-specific IgE, the overall proportion of subjects re-
porting AEs was similar regardless of IgE level (approx. 
66%). However, a greater proportion of subjects with 
high HDM-specific IgE levels (>17.5 kU/L; specific IgE 
class 4–6) experienced treatment-related AEs compared 
to subjects with low specific IgE levels ( ≤ 17.5 kU/L; spe-
cific IgE class 0–3). Specifically, for subjects on active 
treatment, 56% of subjects with high IgE levels experi-
enced treatment-related AEs compared to 34% of sub-
jects with low IgE levels. This trend was also reflected in 
the subgroup analyses presented in  Figures 1 and  2 . While 
the observed differences did not reach statistical signifi-
cance, a trend toward a higher risk of experiencing mod-
erate or severe treatment-related AEs with increasing IgE 
level was observed ( p = 0.05).
 Most Common Treatment-Related AEs 
 Figure 3 provides an overview of the most common 
treatment-related AEs in the 2 clinical trials (defined as 
treatment-related AEs reported by  ≥ 5% of subjects on ac-
tive treatment). All were local allergic reactions; the most 
common was oral pruritus, as reported by 20% of subjects 
on active treatment, followed by throat irritation (12%) 
and mouth oedema (10%).
 The onset and duration of the most common treat-
ment-related AEs were further investigated. In general, 
the most common treatment-related AEs occurred with-
in the first few days of treatment with the SQ HDM SLIT-
tablet and lasted for approximately 5 min after tablet in-
take (data not shown).
 In  Figure 4 , the first onset of the most common ( ≥ 5%) 
treatment-related AEs is presented as the percentage of 
subjects experiencing a new AE during each week of the 
first year of treatment. In both treatment groups, the pro-
portion of subjects experiencing onset of a new AE was 
greatest during the first week of treatment (approximate-
ly 33% of subjects on active treatment, 5% of subjects on 
placebo). By week 2, the proportions had dropped con-
siderably to fewer than 3% of subjects in both groups. 
Thus, for most subjects experiencing the most common 
treatment-related AEs, these local allergic reactions oc-
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curred for the first time during the first week of treatment. 
In contrast, very few subjects experienced one of these 
reactions for the first time later than 5 weeks after treat-
ment initiation.
 The median duration (defined as the time from start 
to stop of each individual AE in a given subject) for the 
most common treatment-related AEs were as follows: 
oral pruritus 6 days, throat irritation 9 days, and mouth 
oedema 21 days (all for subjects on active treatment); 19% 
of subjects on active treatment had at least 1 of the most 
common treatment-related AEs ongoing in week 4 of the 
trial. After 12 and 24 weeks, this proportion was reduced 
to 14 and 7%, respectively (online suppl. Fig. S1). 
 Severe Treatment-Related AEs 
 A summary of all severe treatment-related AEs and 
treatment-related SAEs experienced by subjects in the 
groups on 12 SQ-HDM in the 2 trials are listed in  Table 3 . 
Most of these cases were local allergic reactions.
 One severe treatment-related AE of asthma was re-
ported in the MT-04 trial, 8.5 months after the initial ad-
ministration of the SQ HDM SLIT-tablet. The subject de-
veloped a severe asthma exacerbation. Initially, the exac-
erbation was treated with ICS and short-acting β-agonists. 
Later, oral corticosteroid was added due to lack of effi-
cacy of the initial treatment, and treatment with the SQ 
HDM SLIT-tablet was discontinued 7 days after the onset 
of the AE. On day 9, an antibiotic was added, and 2 days 
later the subject was additionally treated with intravenous 
steroid. The subject recovered on day 16 after the start of 
the AE.
 Treatment-Related SAEs 
 Table  3 provides an overview of treatment-related 
SAEs experienced by subjects on active treatment. While 
no treatment-related SAEs were reported by subjects on 
12 SQ-HDM in the MT-06 trial, 1 treatment-related SAE 
was reported as asthma exacerbation in the MT-04 trial. 
The subject developed worsening of respiratory symp-
toms over the first 6 days after the initiation of treatment 
with the SQ HDM SLIT-tablet (reported as asthma exac-
erbation and assessed as moderate by the investigator). 
The event was classified as serious due to hospitalisation 
of the subject (on day 8). Treatment included systemic 
and inhaled corticosteroids and long-acting β 2 -agonist. 
The subject was discontinued from the trial on day 6 and 
recovered fully. The subject had a viral infection in the 
period prior to initiation of treatment with the SQ HDM 
SLIT-tablet. According to the investigator, an alternative 
aetiology was a recent viral infection.
 Table 3.  Overview of all severe treatment-related AEs and treatment-related SAEs reported by subjects on 12 
SQ-HDM in the 2 trials
Trial Dose MedDRA preferred term Action taken to inter-
vention medication
Day of
onset
Duration,
days
Severe treatment-related AEs
MT-04 12 SQ-HDM Submaxillary gland enlargement Discontinued 8 2
MT-04 12 SQ-HDM Mouth oedema Discontinued 2 5
MT-04 12 SQ-HDM Tongue oedema Discontinued 38 37
MT-04 12 SQ-HDM Oral pruritus Discontinued 38 NR
MT-04 12 SQ-HDM Dysphagia Interrupted 1 153
MT-04 12 SQ-HDM Asthma Discontinued 257 16
MT-06 12 SQ-HDM Throat irritation Discontinued 1 83
MT-06 12 SQ-HDM Mouth oedema Discontinued 15 11
MT-06 12 SQ-HDM Oral pain Discontinued 15 11
MT-06 12 SQ-HDM Lip oedema None 274 1
MT-06 12 SQ-HDM Throat irritation None 1 1
MT-06 12 SQ-HDM Oral pruritus None 1 1
Treatment-related SAEsa
MT-04 12 SQ-HDM Asthma exacerbation
(moderate)
Discontinued 1 79
 AE, adverse event; SAE, serious adverse event; MedDRA, Medical Dictionary for Regulatory Activities; NR, 
not recovered. a Assessed as serious by investigator or sponsor.
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 Adverse Reactions of Special Interest 
 No deaths or cases of anaphylactic shock were report-
ed in the 2 trials and no events were reported as systemic 
allergic reactions. No treatment-related AEs involved lo-
cal allergic swelling compromising the airways.
 In the MT-06 trial, a treatment-related AE reported by 
the investigator as “very mild laryngeal oedema, no vital 
risk” was treated with adrenaline. This reaction occurred 
with 12 SQ-HDM upon initial administration of the SQ 
HDM SLIT-tablet, which was performed under medical 
supervision as required by the protocol. The second ad-
ministration was also performed under medical supervi-
sion, and the subject completed the trial with mild oral 
pruritus as the only subsequently reported treatment-re-
lated AE  [37] .
 Discussion 
 This pooled analysis of safety and tolerability of the SQ 
HDM SLIT-tablet (dose 12 SQ-HDM) confirmed that 
treatment is well tolerated by a broad European popula-
tion of adult patients with HDM respiratory allergic dis-
ease. The safety profile was comparable for subjects with 
moderate-to-severe HDM allergic rhinitis and subjects 
with not well-controlled HDM allergic asthma. No unex-
pected safety concerns emerged from the clinical devel-
opment programme of the SQ HDM SLIT-tablet, and the 
overall safety and tolerability profile was similar to that 
observed for other SLIT-tablets, including the authorised 
products GRAZAX/GRASTEK, RAGWITEK, ACTAIR, 
and ORALAIR  [16–21, 23] .
 Since treatment with the SQ HDM SLIT-tablet involves 
administering to patients the allergen causing their allergy 
symptoms, local allergic reactions are to be expected dur-
ing treatment. Accordingly, the pooled safety data showed 
a greater proportion of subjects on active treatment re-
porting treatment-related AEs compared to placebo. Most 
reported AEs were mild or moderate local allergic reac-
tions occurring within the first few days of treatment ini-
tiation. For most subjects, the local treatment-related AEs 
were resolved within days to weeks, but a small subset ap-
peared to have more persistent, mild local AEs occurring 
daily throughout the treatment period. The duration in 
minutes of these treatment-related AEs was not assessed 
in the phase III trials but is known from phase I trials to 
be in the range of minutes to hours  [27] . In case a patient 
experiences significant local adverse reactions due to 
treatment with the SQ HDM SLIT-tablet, anti-allergic 
medication (e.g., antihistamines) is recommended.
 In the pooled dataset, approximately one-third of sub-
jects were only sensitised to HDM, whereas most were 
sensitised to additional allergens. The safety analysis re-
vealed no differences in safety and tolerability of the SQ 
HDM SLIT-tablet based on subjects’ sensitisation status.
 In the investigated populations, a dose of 12 SQ-HDM 
had a safety and tolerability profile that supports at-home 
sublingual administration once the first tablet is tolerated 
when administered under physician supervision. In addi-
tion, the requirement for at least 30 min of monitoring 
after the initial administration of the SQ HDM SLIT-tab-
let provides an opportunity for discussion and possible 
treatment of any immediate AEs.
 A potential concern with SLIT is the risk of severe local 
allergic reactions leading to swelling which may compro-
mise the airways. Across the trials included in the present 
safety analysis, 10% of subjects on active treatment re-
ported the local treatment-related AE mouth oedema, 
and a small number of severe local treatment-related AEs 
were reported. No events involving compromised air-
ways were reported and the treatment-related AEs were 
all manageable. In addition, no AEs were reported as sys-
temic allergic reactions. As such, nothing in the pooled 
safety data suggests a need for co-prescription of adrena-
line auto-injectors during treatment with the SQ HDM 
SLIT-tablet, as is currently a requirement for initiating 
SLIT-tablet treatment in the US (but not in Europe or 
elsewhere).
 An important aspect of this safety investigation is the 
assessment of patients with HDM allergic asthma. Severe 
uncontrolled asthma is a known risk factor for anaphy-
laxis  [38–40] and is believed to constitute a risk during 
AIT, even if AIT is also used to treat allergic asthma  [11] . 
Thus, AIT is often contraindicated in patients with un-
controlled or severe asthma  [41] . In this paper, safety data 
from 2 large trials were analysed to reveal differences in 
safety and tolerability that might arise from differences in 
the manifestation and severity of HDM respiratory aller-
gic disease. With regard to treatment-related AEs, no sig-
nificant differences based on asthma, asthma medication 
level, or asthma control were observed. The overall com-
parison (of all AEs, not only those related to the treat-
ment) indicated that subjects with not well-controlled 
asthma (in both placebo and active groups) experienced 
more AEs of a higher severity and had more discontinu-
ations due to AEs compared with the population with 
controlled asthma in general.
 Because of the known risk in asthma, patients with 
FEV 1 <70% of the predicted value after adequate pharma-
cological treatment at randomisation and patients who 
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had experienced a severe asthma exacerbation within the 
last 3 months prior to randomisation were not investi-
gated in the clinical development programme. Within 
these safety precautions, the MT-04 trial included a sub-
group of subjects with HDM allergic asthma that was un-
controlled at randomisation according to the GINA 2010 
definition of uncontrolled asthma  [42] . There was no ev-
idence of active treatment affecting this subgroup any dif-
ferently with respect to treatment-related AEs compared 
to subjects with controlled asthma.
 Although the SQ HDM SLIT-tablet has been shown to 
improve HDM allergic asthma symptoms, the risk of 
acute asthma exacerbation remains for patients with risk 
factors, as observed by the reported treatment-related 
SAE in the MT-04 trial where a patient with recent viral 
infection developed a moderate asthma exacerbation 
within the first week of the trial. Thus, great care should 
be exercised in assessing patients’ asthma status and risk 
factors (such as ongoing viral infection, recent severe ex-
acerbation, and FEV 1 <70%), even though the SQ HDM 
SLIT-tablet has been shown to be well tolerated in sub-
jects with HDM allergic asthma not well controlled by 
ICS, regardless of asthma control level according to the 
GINA 2010 criteria  [42] .
 In conclusion, the presented results from 2 large ran-
domised placebo-controlled trials including 1,215 sub-
jects show that the SQ HDM SLIT-tablet (dose 12 SQ-
HDM) is well tolerated and suitable for at-home admin-
istration in patients with HDM respiratory allergic 
disease. This includes patients with asthma symptoms 
not well controlled by allergy pharmacotherapy provided 
that their lung function allows (FEV 1 >70%) and that 
their asthma status, including risk factors such as recent 
viral infection, is carefully assessed. Mild-to-moderate 
local allergic reactions are common and usually occur at 
treatment initiation and subside with continued treat-
ment.
 Acknowledgements 
 The authors present this publication on behalf of all the in-
volved investigators from the 2 trials. The authors would like to 
thank all investigators and especially the principal investigators of 
the 2 trials, Dr. Johann Christian Virchow (MT-04) and Dr. Pascal 
Demoly (MT-06). The trials were funded by ALK. In this context, 
the authors would like to thank the clinical trial teams at ALK for 
clinical project management, operational oversight, safety moni-
toring, data management, and statistical analyses. Medical writers 
Brian Sonne Stage and Ida Mosbech Smith, ALK, were responsible 
for medical writing, editorial, and journal submission assistance 
for this manuscript.
 Disclosure Statement 
 W. Emminger has been involved in several clinical studies for 
ALK. M.D. Hernández was a primary investigator in the MT-04 
trial and has served on advisory boards for ALK. V. Cardona has 
received fees as advisor, speaker, or researcher for ALK, Allergo-
pharma, Allergy Therapeutics, Astra, Circassia, HAL, FAES, GSK, 
LETI, Novartis, Shire, Stallergenes, and Uriach. F. Smeenk was a 
scientific advisory board member for ALK regarding the MT-04 
trial and has received speaking fees from ALK. B.S. Fogh is em-
ployed by ALK, the manufacturer of the SQ HDM SLIT-tablet. 
M.A. Calderon has received advisory fees from ALK and Hal Al-
lergy and has received lecture fees from ALK, Allergopharma, Hal 
Allergy, Merck, and Stallergenes-Greer. F. de Blay has received re-
search support from Chiesi and Stallergenes and consultancy fees 
from ALK, Mundipharma, and Novartis, and has served as a board 
member for ALK, Boehringer, Medapharma, Mundipharma, No-
vartis, and Stallergenes. V. Backer has been involved in several 
clinical studies for ALK and has received investigator fees and pa-
tient fees.
 
 References 
 1 Bousquet J, Van Cauwenberge P, Khaltaev N; 
Aria Workshop Group; World Health Orga-
nization: Allergic rhinitis and its impact on 
asthma. J Allergy Clin Immunol 2001; 
 108:S147–S334. 
 2 Linneberg A, Henrik Nielsen N, Frolund L, 
Madsen F, Dirksen A, Jorgensen T: The link 
between allergic rhinitis and allergic asthma: 
a prospective population-based study. The 
Copenhagen Allergy Study. Allergy 2002; 57: 
 1048–1052. 
 3 Bousquet J, Khaltaev N, Cruz AA, et al: Aller-
gic rhinitis and its impact on asthma (ARIA) 
2008 update (in collaboration with the World 
Health Organization, GA 2 LEN and Aller-
Gen). Allergy 2008; 63(suppl 86):8–160. 
 4 Bauchau V, Durham SR: Prevalence and rate 
of diagnosis of allergic rhinitis in Europe. Eur 
Respir J 2004; 24: 758–764. 
 5 Gotzsche PC, Johansen HK: House dust mite 
control measures for asthma: systematic re-
view. Allergy 2008; 63: 646–659. 
 6 Valovirta E, Myrseth SE, Palkonen S: The 
voice of the patients: allergic rhinitis is not a 
trivial disease. Curr Opin Allergy Clin Immu-
nol 2008; 8: 1–9. 
 7 Canonica GW, Tarantini F, Complati E, Pen-
agos M: Efficacy of desloratadine in the treat-
ment of allergic rhinitis: a meta-analysis of 
randomized, double-blind, controlled trials. 
Allergy 2007; 62: 359–366. 
 8 Radulovic S, Calderon MA, Wilson D, Dur-
ham S: Sublingual immunotherapy for aller-
gic rhinitis. Cochrane Database Syst Rev 2010; 
 12:CD002893. 
 9 Creticos PS, Reed CE, Norman PS, et al: Rag-
weed immunotherapy in adult asthma. N 
Engl J Med 1996; 334: 501–506. 
 10 Compalati E, Passalacqua G, Bonini M, Ca-
nonica GW: The efficacy of sublingual immu-
notherapy for house dust mites respiratory al-
lergy: results of a GA 2 LEN meta-analysis. Al-
lergy 2009; 64: 1570–1579. 
 11 GINA Executive Committee, Global Initiative 
for Asthma: Global Strategy for Asthma Man-
agement and Prevention. Bethesda, National 
Heart, Lung and Blood Institute, National In-
stitute of Health, 2016. 
 Emminger   et al.
 
Int Arch Allergy Immunol 2017;174:35–44
DOI: 10.1159/000478699
44
 12 Amin HS, Liss GM, Bernstein DI: Evaluation 
of near-fatal reactions to allergen immuno-
therapy injections. J Allergy Clin Immunol 
2006; 117: 169–175. 
 13 Bernstein DI, Wanner M, Borish L, Liss GM; 
Immunotherapy Committee, American 
Academy of Allergy, Asthma and Immunol-
ogy: Twelve-year survey of fatal reactions to 
allergen injections and skin testing: 1990–
2001. J Allergy Clin Immunol 2004; 113: 1129–
1136. 
 14 Cox L, Nelson H, Lockey R, et al: Allergen im-
munotherapy: a practice parameter third up-
date. J Allergy Clin Immunol 2011; 127:S1–
S55. 
 15 Pfaar O, Bachert C, Bufe A, et al: Guideline on 
allergen-specific immunotherapy in IgE-me-
diated allergic diseases. Allergo J Int 2014; 23: 
 282–319. 
 16 Bergmann K, Demoly, Worm M, et al: Effi-
cacy and safety of sublingual tablets of house 
dust mites allergen extracts in adults with al-
lergic rhinitis. J Allergy Clin Immunol 2014; 
 133: 1608–1614. 
 17 Blaiss M, Maloney J, Nolte H, Gawchik S, Yao 
R, Skoner DP: Efficacy and safety of timothy 
grass allergy immunotherapy tablets in North 
American children and adolescents. J Allergy 
Clin Immunol 2011; 127: 64–71. 
 18 Cox LS, Casale TB, Nayak AS, et al: Clinical 
efficacy of 300IR 5-grass pollen sublingual 
tablet in a US study: the importance of aller-
gen-specific serum IgE. J Allergy Clin Immu-
nol 2012; 130: 1327–1334. 
 19 Creticos PS, Maloney J, Bernstein DI, et al: 
Randomized controlled trial of a ragweed al-
lergy immunotherapy tablet in North Ameri-
can and European adults. J Allergy Clin Im-
munol 2013; 131: 1342–1349. 
 20 Durham SR, Yang WH, Pedersen MR, Johan-
sen N, Rak S: Sublingual immunotherapy 
with once-daily grass allergen tablets: a ran-
domized controlled trial in seasonal allergic 
rhinoconjunctivitis. J Allergy Clin Immunol 
2006; 117: 802–809. 
 21 Maloney J, Bernstein DI, Nelson H, et al: Ef-
ficacy and safety of grass sublingual immuno-
therapy tablet, MK-7243: a large randomized 
controlled trial. Ann Allergy Asthma Immu-
nol 2014; 112: 146–153. 
 22 Mosbech H, Canonica GW, Backer V, et al: 
SQ house dust mite sublingually administered 
immunotherapy tablet (ALK) improves aller-
gic rhinitis in patients with house dust mite 
allergic asthma and rhinitis symptoms. Ann 
Allergy Asthma Immunol 2015; 114: 134–140. 
 23 Nelson HS, Nolte H, Creticos P, Maloney J, 
Wu J, Bernstein DI: Efficacy and safety of tim-
othy grass allergy immunotherapy tablet 
treatment in North American adults. J Allergy 
Clin Immunol 2011; 127: 72–80. 
 24 Virchow JC, Backer V, Kuna P, et al: Efficacy 
of a house dust mite sublingual allergen im-
munotherapy tablet in adults with allergic 
asthma: a randomized clinical trial. JAMA 
2016; 315: 1715–1725. 
 25 Demoly P, Emminger W, Rehm D, Backer V, 
Tommerup L, Kleine-Tebbe J: Effective treat-
ment of house dust mite-induced allergic rhi-
nitis with 2 doses of the SQ HDM SLIT-tablet: 
results from a randomized double-blind, pla-
cebo-controlled phase III trial. J Allergy Clin 
Immunol 2016; 137: 444–451. 
 26 Incorvaia C, Masieri S, Berto P, Scurati S, Fra-
ti F: Specific immunotherapy by the sublin-
gual route for respiratory allergy. Allergy 
Asthma Clin Immunol 2010; 6: 29. 
 27 Corzo JL, Carrillo T, Pedemonte C, et al: Tol-
erability during double-blinded randomised 
phase I trials with the house dust mite allergy 
immunotherapy tablet in adults and children. 
J Investig Allergol Clin Immunol 2014; 24: 
 154–161. 
 28 Okubo K, Masuyama K, Imai T, et al: Efficacy 
and safety of the SQ house dust mite sublin-
gual immunotherapy tablet in Japanese adults 
and adolescents with house dust mite-in-
duced allergic rhinitis. J Allergy Clin Immu-
nol 2017; 139: 1840–1848. 
 29 de Blay F, Kuna P, Prieto L, et al: SQ HDM 
SLIT-tablet (ALK) in treatment of asthma – 
post hoc results from a randomised trial. 
Respir Med 2014; 108: 1430–1437. 
 30 Nolte H, Bernstein DI, Nelson HS, et al: Effi-
cacy of house dust mite sublingual immuno-
therapy tablet in North American adolescents 
and adults in a randomized, placebo-con-
trolled trial. J Allergy Clin Immunol 2016; 138: 
 1631–1638. 
 31 Mosbech H, Deckelmann R, de BF, et al: Stan-
dardized quality (SQ) house dust mite sublin-
gual immunotherapy tablet (ALK) reduces 
inhaled corticosteroid use while maintaining 
asthma control: a randomized, double-blind, 
placebo-controlled trial. J Allergy Clin Immu-
nol 2014; 134: 568–575. 
 32 Nolte H, Maloney J, Nelson HS, et al: Onset 
and dose-related efficacy of house dust mite 
sublingual immunotherapy tablets in an envi-
ronmental exposure chamber. J Allergy Clin 
Immunol 2015; 135: 1494–1501. 
 33 World Medical Association: Declaration of 
Helsinki: Ethical Principles for Medical Re-
search Involving Human Subjects. Adopted 
by the WMA General Assembly in Helsinki 
(1964) and as amended by the WMA General 
Assembly, 2008. 
 34 International Conference on Harmonization: 
ICH Harmonised Tripartite Guideline Topic 
E6(R1): Guideline for Good Clinical Practice. 
1996. 
 35 Henmar H, Frisenette SM, Grosch K, et al: 
Fractionation of source materials leads to a 
high reproducibility of the SQ house dust 
mite SLIT-tablets. Int Arch Allergy Immunol 
2016; 169: 23–32. 
 36 International Conference on Harmonization: 
ICH Harmonised Tripartite Guideline Topic 
E2A. Clinical Safety Data Management: Defi-
nitions and Standards for Expedited Report-
ing. 1994. 
 37 Demoly P, Emminger W, Rehm D, Backer V, 
Tommerup L, Kleine-Tebbe J: Effective treat-
ment of house dust mite-induced allergic rhi-
nitis with 2 doses of the SQ HDM SLIT-tablet: 
results from a randomized double-blind, pla-
cebo-controlled phase III trial. J Allergy Clin 
Immunol 2016; 137: 444–451. 
 38 Lieberman P, Nicklas RA, Oppenheimer J, et 
al: The diagnosis and management of anaphy-
laxis practice parameter: 2010 update. J Al-
lergy Clin Immunol 2010; 126: 477–480. 
 39 Muraro A, Roberts G, Worm M, et al: Ana-
phylaxis: guidelines from the European Acad-
emy of Allergy and Clinical Immunology. Al-
lergy 2014; 69: 1026–1045. 
 40 Simons FE, Ardusso LR, Bilo MB, et al: World 
Allergy Organization anaphylaxis guidelines: 
summary. J Allergy Clin Immunol 2011; 127: 
 587–593. 
 41 ALK-Abelló A/S: GRAZAX Summary of 
Product Characteristics. 2015. 
 42 GINA Executive Committee, Global Initiative 
for Asthma: Global Strategy for Asthma Man-
agement and Prevention. Bethesda, National 
Heart, Lung and Blood Institute, National In-
stitute of Health, 2010. 
 
